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Objective: to establish if gravidity and parity associate with the development of rheumatoid 
arthritis (RA), and to establish if this effect is influenced by the time elapsed since 
pregnancy/childbirth, the number of pregnancies/childbirths, and serological status, through 
systematically reviewing the literature and undertaking a meta-analysis.  
 
Methods: we searched Medline/EMBASE (from 1946-2018) using the terms “rheumatoid 
arthritis.mp” or “arthritis, rheumatoid/” and “pregnancy.mp” or “pregnancy/” or “parity.mp” 
or “parity/” or “gravidity.mp” or “gravidity/” (observational study filter applied). Case-
control/cohort studies that examined the relationship between parity/gravidity and the risk of 
RA in women were included. Studies reporting effect size data for RA in ever vs. never 
parous/gravid women as ORs/RRs with 95% confidence intervals were included in a meta-
analysis. Other relationships (i.e. risk by pregnancy/childbirth numbers) were analysed 
descriptively. 
 
Results: twenty studies (from 626 articles) met our inclusion criteria, comprising 14 case-
control (4,799 cases; 11,941 controls) and 6 cohort studies (8,575 cases; 2,368,439 
individuals). No significant association was observed in the meta-analysis of studies reporting 
the risk of RA in ever vs. never parous women (OR 0.91; 95% CI 0.80-1.04) and ever vs. never 
gravid women (OR 0.86; 95% CI 0.46-1.62). No consistent evidence of a relationship between 
the number of pregnancies/childbirths and RA risk was seen. No significant association was 





Conclusion: our systematic review does not support the concept that gravidity and parity are 
associated with the risk of RA development. 
 




1. INTRODUCTION  
Rheumatoid arthritis (RA) is a complex disease, resulting from a range of gene-environment 
risk factors (1). The main environmental RA risk factor is cigarette smoking, demonstrated 
across various studies to increase the risk of RA development, particularly seropositive disease 
(2). Alcohol consumption may reduce the risk of RA, although this association has generally 
been reported in case-control studies subject to recall bias (3). The roles of other environmental 
risk factors, including periodontitis (4,5) and caffeine intake (6,7), are less well-established 
with positive associations often not replicated across studies. The increasing interest in 
identifying people at a high-risk of RA (8) in whom preventative strategies could be evaluated, 
means it is vital to accurately define risk factors contributing to RA development. 
 
Previous research suggests pregnancy (gravidity) and childbirth (parity) have a complex 
relationship with RA. A recent systematic review by Jetwha et al (9) has confirmed the 
observation first made by Hench in 1938 that disease activity often reduces during pregnancy 
and flares in the post-partum period (10). A broad range of studies have also evaluated whether 
gravidity and parity are risk factors for the development of RA. The general trend appears to 
be that the risk of RA development is reduced during pregnancy (11,12), increases in the post-
partum period (11,12), and is subsequently reduced in those that have previously been pregnant 
or given birth (13–15).  The “protective effect” of previous pregnancy and childbirth has not, 
however, been replicated across all studies (16–18), and its precise impact on RA susceptibility 
remains uncertain. To date, one systematic literature review and meta-analysis has been 
undertaken in this area, reporting an inverse relationship between parity and RA risk (19). This 
review did not, however, evaluate risk by gravidity or childbirth timing, and included results 
from different analyses undertaken in the same patient groups (including two publications from 




We have, therefore, undertaken a systematic literature review of observational studies 
evaluating the association between gravidity and parity, and the risk of developing RA. Our 
primary aim was to examine the risk of developing RA in previously gravid/parous women 
compared to non-gravid/parous women, by testing the hypothesis that previous gravidity/parity 
influenced the likelihood of RA development. Our secondary aims were to examine: (1) the 
risk of developing RA during the partum and immediate post-partum periods; (2) the risk of 
developing RA by the number of pregnancies/childbirths; (3) if these risks are different for 
seropositive and seronegative disease. 
 
2. METHODS 
2.1 Reporting and Data Extraction 
We followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
guidelines for the reporting of our review (23). The literature search, and study quality 
assessments were performed separately by two authors (WYMC/SS). Data extraction was 
undertaken by one author (WYMC), and checked for accuracy by a second author (SS). 
Discrepancies were resolved by discussion, with involvement of a third researcher (ICS) if 
necessary. Inclusion criteria/analytical methods (detailed below) were pre-specified. The 





2.2 Search Strategy 
The literature search was conducted using the Ovid platform in January 2018 using Medline 
(1946 to January 2018) and Embase Classic and Embase (1947 to January 2018).   The 
following search terms were used: “rheumatoid arthritis.mp” or “arthritis, rheumatoid/” and 
“pregnancy.mp” or “pregnancy/” or “parity.mp” or “parity/” or “gravidity.mp” or “gravidity/”. 
The Scottish Intercollegiate Guidelines Network (SIGN) observational study filter was applied 
(25), and the search limited to “humans”. Citations were exported to the EndNote programme. 
Duplicates were removed. Articles were further removed by screening titles and/or abstracts. 
Additional articles were included from reference lists of identified papers, if they fulfilled 
inclusion criteria.  
 
2.3 Selection Criteria 
We included observational studies that (1) were case control/cohort design; (2) examined the 
relationship between gravidity and/or parity and the risk of RA development in women. Studies 
reporting effect size data for RA development in ever vs. never gravid or ever vs. never parous 
women as odds ratios (ORs) or relative risks (RRs) with 95% CIs were included in a meta-
analysis. 
 
We excluded (1) studies evaluating the same cohort (including the most comprehensive and 
recent); (2) unpublished studies (conference abstracts); (3) other study designs (case-
reports/series, systematic reviews); (4) studies evaluating other risk factors.   
 
2.4 Data Extraction 
The following were extracted: publication year; author names; location; design; sample size; if 
risk was reported by parity, gravidity, number of pregnancies/childbirths, or serological status; 
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method of assessing parity/gravidity; effect size data; adjustment factors; RA definition; age 
range; P-value for trend (between number of pregnancies/childbirths and RA risk).   
 
2.5 Study Quality 
The Newcastle-Ottawa Scale (NOS) assessed study quality.  This comprises a “star system” 
judging studies on three domains: (1) selection of study groups; (2) comparability of groups; 
(3) ascertainment of exposure/outcome of interest. A maximum of 9 stars indicates the highest 
quality study (26).  
 
2.6 Statistical Analysis 
2.6.1 Meta-Analysis of RA Risk in Ever vs. Never Gravid Women or Ever Vs. Never Parous 
Women 
The OR is considered a good estimate of the population RR when the disease/outcome 
prevalence is <10% (27). As the UK adult RA prevalence is ~0.81% (28), ORs and RRs were 
used interchangeably (29). This approach is consistent with meta-analyses of other RA risk 
factors (2,3,30)). In studies where OR/RR were reported using ever-pregnant as the reference 
group, the reciprocal was taken, to obtain an OR/RR using never-pregnant as the reference 
group. A random-effects model based on DerSimonian and Laird’s approach was used, due to 
heterogeneity across studies (31). Cohort and case-control study data were analysed both 
together and separately, with pooled ORs/RRs reported in both instances.  The most adjusted 
ORs/RRs from each study were included in the meta-analysis.  P-values <0.05 were considered 





2.6.2 Heterogeneity Assessment 
Between study heterogeneity was assessed using Cochran’s Q-test and the I2-statistic. The 
former tests the null hypothesis that homogeneity exists between the sample estimates of the 
population parameter across studies, and any variation between them is a result of sampling 
error (32). The latter describes the percentage of total variation across studies due to 
heterogeneity rather than chance. It ranges from 0% (no heterogeneity) to 100% (high 
heterogeneity) (33). 
 
2.6.3 Publication Bias 
Publication bias was looked for by constructing funnel plots and using the “trim-and-fill” 
method. This data augmentation technique estimates the number of studies missing from a 
meta-analysis due to suppression of the most extreme results on one side of the plot, and 
augments the observed data, delivering a more symmetrical plot (34).   
 
2.6.4 Analysis of Other Risk Types 
Other risk periods or influences, such as the risk of RA in the partum, or post-partum period, 
and risk by the number of childbirths/pregnancies, or serological status were analysed 
descriptively. This is because of the heterogeneity between studies in (a) their definition of the 
post-partum period (with risk reported in the first 3 months (12), first 12 months (35), and many 
years post-partum (20)); (b) their categorisation of number of childbirths/pregnancies by which 
risk was reported, or (c) the small numbers of studies assessing these issues (e.g. only 2 studies 





2.6.5 Programme Used 
Meta-analysis and funnel plots were undertaken using R, version 3.5.0. (R Foundation for 
Statistical Computing, Vienna, Austria), and the package “Metafor” (37). 
 
3. RESULTS 
3.1 Studies Identified 
626 articles were screened. All identified abstracts were published in English; we did not 
identify any studies in non-English languages fulfilling our inclusion criteria from abstract 
review. 604 were excluded (by abstract/title), providing 22 articles for full text review (Figure 
1). Of these, 9 were excluded for the following reasons: 2 evaluated the same cohort (22,38); 
3 were conference abstracts (39–41), 3 were review articles (42–44), and one was a meta-
synthesis of a range of RA risk factors (45).  7 studies were added from the reference lists of 
included articles (12,15,35,46–48). 
 
20 studies meeting our inclusion criteria were included in the analysis; 6 were cohort, and 14 
case-control studies (Table 1). 14 studies reported the risk of RA in relation to being ever-
gravid or ever-parous (13–16,18,20,35,36,42,48–53), 11 reported the risk of RA in relation to 
the number of previous pregnancies or childbirths (13,16,18,20,46,48–51,54,55), 9 reported 
the risk of RA in relation to the timing of pregnancy (11,12,14,17,20,35,36,46,47), and 2 
reported the risk in relation to serological status (18,36).  
 
3.2 Cohort Studies 
3.2.1 Overview 
The six cohort studies included 8,575 incident RA cases from a total population size of 
2,368,439 individuals (Table 1). Two were undertaken in North America and four in Europe. 
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Publication year ranged from 1995 to 2014. Four studies attained information on 
gravidity/parity by questionnaire, one by interview and one using registry data. 
 
3.2.2 Study Quality 
Four cohort studies had Newcastle-Ottawa scores of 7, and two studies had scores of 6 (Table 
1). Five studies lost one star for not mentioning follow-up rates (18,49,50,54,55).  Four studies 
lost one star for “ascertainment of exposure” due to using self-reported questionnaires 
(16,18,50,54), and three studies lost one star for not demonstrating the outcome (RA) was 
absent at the study start (49,54,55). One study lost one star for “comparability” for only 
adjusting risk for age (50). One study lost one star for the “exposed cohort” being a selected 
group of individuals (nurses) (16).   
 
 
3.3 Case-Control Studies 
3.3.1 Overview 
The 14 case-control studies totalled 4,799 cases and 11,941 controls. Four were undertaken in 
North America, and 10 in Europe. Publication year ranged from 1989 to 2014. Seven studies 
attained information on gravidity/parity by questionnaire, two from medical records, and five 
by interview.  
 
3.3.2 Study Quality 
One study had a Newcastle-Ottawa score of 5, eleven studies had scores of 6, and one study 
had a score of 7 (Table 1). One study contained insufficient data to undertake a quality 
assessment (14). All studies with data available to assess quality lost one star for “non-response 
rate” as they failed to show an equal non-response rate in cases and controls, or response rates 
were not described, and lost one star for “ascertainment of exposure” as they either used non-
11 
 
blinded interviews or self-reported questionnaires.  One study lost one star for “adequacy of 
case definition” as it used record linkage to identify cases (51). One study lost one star for “case 
representativeness” as cases were twins (35).  Three studies lost one star for “control selection” 
as hospital population controls were used (12,13), or controls were unaffected first and second-
degree relatives (46).  Seven studies lost one star for “control definition” as they did not 
explicitly state controls had no history of RA (15,20,35,36,47,48,53).  One study lost one star 
for “comparability” due to not demonstrating adjustment for additional confounders (52). 
 
3.4 Risk of RA by Previous Parity and Gravidity Status 
3.4.1 Meta-Analysis 
Eleven studies reported RA risk in ever vs. never parous women (Table 2). Two studies 
reported a significantly reduced risk of RA; the remaining studies reported no significant 
association. Combining these in a meta-analysis (Figure 2) showed no significant association 
between ever vs. never-parity and RA (OR 0.91; 95% CI 0.80-1.04). No significant 
association was seen when the analysis was restricted to cohort (OR 0.96; 95% CI 0.89-1.03) 
and case-control (OR 0.81; 95% CI 0.61-1.08) studies. Low-to-moderate heterogeneity levels 
were observed (I2=38.4%; P=0.09). 
 
Four studies reported RA risk in ever vs. never gravid women (Table 2). One study reported a 
significantly reduced risk of RA, one reported a reduced OR without providing data on its 
significance, and two reported no significant association. Combining the three studies with 
95% CI data in a meta-analysis (Supplementary Figure 1) showed no significant association 
between ever vs. never-gravidity and RA (OR 0.86; 95% CI 0.46-1.62). Moderate-to-high 




One study reported RA risk in both ever-parous vs. nulligravid women (significant risk 
reduction seen) and ever-gravid but nulliparous vs. nulligravid women (trend towards 
increased risk seen) (20). Due to different parity and gravidity groupings to the other studies 
it was not included in the meta-analysis. 
 
3.4.2 Individual Study Influences 
Excluding individual studies from our meta-analysis did not result in an overall significant 
association between ever-parous status and RA risk (Supplementary Table 1). 
 
3.4.3 Publication Bias 
There was some evidence of funnel plot asymmetry (Figure 3), with two medium precision 
studies favouring a reduced risk of RA in ever vs. never-parous women, and an absence of 
similar medium precision studies with effect sizes in the opposing direction (shown as white 
circles in the funnel plot). 
 
3.5 Risk of RA by Number of Childbirths or Pregnancies 
Nine studies reported RA risk by number of childbirths. Risk was reported using a variety of 
birth number groupings/reference groups, making these data unsuitable for meta-analysis 
(Table 2). Six studies reported no significant dose-risk trend between the number of childbirths 
and RA risk. Three studies reported some evidence of a dose-risk trend. Firstly, Jørgensen et 
al reported a significantly reduced risk of RA in women having 2 (RR 0.84; 95% CI 0.78-0.90) 
or 3 births (RR 0.83; 95% CI 0.77-0.91) but not ≥4 births (RR 0.89; 95% CI 0.80-1.00) relative 
to 1 childbirth (no P-trend data) (49). Secondly, Lahiri et al reported a significantly increased 
risk of RA for ≥2 births (hazard ratio [HR] 2.55; 95% CI 1.19-5.48), but not 1 birth (HR 1.10; 
95% CI 0.40-3.01) relative to nulliparity (54). Thirdly, Peschken et al reported a significantly 
13 
 
reduced risk of RA in females with ≥6 births (OR 0.43; 95% CI 0.21-0.87) and 3 births (OR 
data not provided), but not 4-5 births (OR data not provided) compared with 1-2 births (P-
trend=0.046) (46). 
 
Two studies reported the risk of RA stratified by the number of pregnancies (13,50). Hazes et 
al reported a greater risk reduction in women with ≥3 pregnancies (OR 0.44; 95% CI 0.22-
0.88) than 1-2 pregnancies (OR 0.53; 95% CI 0.28-0.99) when compared with nulliparity (no 
P-trend data). Merlino et al reported no increased risk by number of pregnancies, using women 
with 1 pregnancy as the reference group and excluding nulligravid women (P-trend 0.30) (50). 
 
3.6 Risk of RA during Pregnancy and Immediate Post-Partum Period 
Four studies reported RA risk during pregnancy (Table 3). One study reported a reduced OR 
for RA, without providing 95% CI data or information on significance (14). In the remaining 
three studies, no significant association was observed, with Brennan et al (35), Lansik et al 
(12), and Silman et al (11), reporting ORs of 0.95 (95% CI 0.19-4.70), 0.64 (95% CI 0.13-
3.21), and 0.3 (95% CI 0.04-2.6), respectively. Combining these within a meta-analysis 
(Supplementary Figure 2) showed no significant association between being pregnant and 
developing RA (OR 0.63; 95% CI 0.23-1.70; I2=0.0%). 
 
Six studies reported the risk of RA during the 12-month post-partum period (Table 3). Brennan 
et al reported no significant association with RA (OR 1.02; 95% CI 0.33-3.16) (35). Del Junco 
et al reported an increased RR (4.67) but did not provide CI or significance data (14). Lansink 
et al reported a trend towards an increased risk <3 months’ post-partum (OR 3.37; 95% CI 
0.86-13.11) and trend towards a reduced risk 3-12 months’ post-partum (OR 0.67; 95% CI 
0.13-3.55) (12). Orellana et al reported a trend towards a reduced risk of ACPA-positive RA 
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(OR 0.8; 95% CI 0.4-1.6) and increased risk of ACPA-negative RA (OR 2.1; 95% CI 0.9-4.8) 
(36). Peschken et al reported a significantly increased risk of RA (OR 3.8; 95% CI 1.45-9.93) 
using >15 years post-partum as the reference group (46). Finally, Silman et al reported an 
increased risk of RA 0-3 months post-partum (OR 5.6; 95% CI 1.80-17.6), and a trend towards 
an increased risk 3-12 months post-partum (OR 2.6; 95% CI 0.8-7.9) (11). 
 
In addition, Rodriguez et al reported the risk of incident RA (over a 12-month period) in women 
that had been pregnant in the previous 12-months (potentially encompassing both the pregnant 
and post-partum period), with a significantly reduced risk of RA seen (OR 0.22; 95% CI 0.06-
0.77) (47). 
 
Two studies reported RA risk in the longer-term post-partum period. Guthrie et al reported a 
marked risk reduction in females 1-5 years post-partum, which was lesser in magnitude at 5-
15 years post-partum, and not significant at >15 years post-partum (20). In contrast, Jørgensen 
et al reported no relationship between the risk of RA, and the time since birth of the most recent 
child (using time categories spanning 0-2 years to >20 years) (17). 
 
3.7 Risk of RA by Serological Status 
Two studies reported RA risk stratified by serological status. Heliövaara et al reported risk for 
RF-positive vs. RF-negative RA by parity status, with no significant association observed with 
either disease subtype (age adjusted RR of RF-positive and RF-negative RA in ever vs. never 
parous women of 1.26 (95% CI 0.82-1.92) and 0.80 (95% CI 0.48-1.32), respectively)  (18). 
Orellana et al reported risk for ACPA-positive vs. ACPA-negative RA by parity status, 
stratified by age (36). In women aged 18-44 years an increased risk for ACPA-negative (OR 
2.1; 95% CI 1.4-3.2) but not ACPA-positive RA (OR 0.9; 95% CI 0.7-1.2) in ever vs. never-
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parous women was reported (adjusting for age and residential area). In women aged 45-70 
years no association was seen (ACPA-negative RA OR 0.9 (95% CI 0.7-1.3); ACPA-positive 
RA OR 1.0 (95% CI 0.8-1.2)). 
 
4. DISCUSSION 
Our systematic review provides a comprehensive summary of research exploring the 
association between parity, gravidity and the risk of developing RA in women. It has three 
main findings. Firstly, no significant association was seen between being ever-parous or ever-
gravid and the risk of developing RA in women, when published study results were combined 
in a meta-analysis. Secondly, no clear dose-risk relationship existed between the number of 
childbirths a woman has experienced and their risk of developing RA. Thirdly, no significant 
association was observed between being pregnant, or in the immediate post-partum period and 
the risk of developing RA. When considered together, these findings do not support the concept 
that pregnancy and childbirth are associated with the risk of developing RA in women. 
 
It is notable that the only studies reporting a significant association between RA and 
parity/gravidity were of case-control design. Whilst case-control studies can provide important 
findings at relatively little time and monetary costs in comparison to cohort studies, they are 
susceptible to a range of biases influencing their reliability (56). Schulz et al recommended that 
good quality case-control studies require: (1) controls that are disease-free and representative 
of the population at risk; (2) data gatherers trained to capture information from cases and 
controls in a similar manner, and blinded to case-control status; (3) confounding to be 
addressed (56). All of the four case-control studies reporting a significantly reduced risk of RA 
according to parity/gravidity (13,15,20,53) did not adhere to at least one of these concepts. 
Hazes et al (13) used controls with musculoskeletal conditions attending the rheumatology 
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department, and did not blind interviewers to case-control status; Reckner-Olsson et al (15) 
and Spector et al  (53) obtained information by questionnaire; Guthrie et al  (20) captured data 
via non-blinded interviewers. 
 
There are several complexities when considering the relationship between gravidity and 
parity and RA risk that merit discussion. Firstly, patients with RA appear to be less fertile 
than people without RA (57). This was demonstrated in two large Scandinavian cohort 
studies, one of which showed that women with RA take longer to conceive and are more 
likely to be treated for infertility (58), with the other showing that women with RA have 
smaller families and longer inter-pregnancy intervals (59). Consequently, higher infertility 
rates in RA could provide the appearance in case-control studies that pregnancy/childbirth 
reduces RA risk. Secondly, breast-feeding has been reported to be significantly associated 
with a lower risk of RA (60). As only parous women will be able to breastfeed, any 
relationship between parity and RA risk could be mediated by breastfeeding. 
 
It is noteworthy that only two of the studies identified in this review reported risk by serological 
status; this meant we could make no conclusions on whether serological status affected the 
impact of parity or gravidity on the risk of developing RA. It is established that the genetic 
architectures of ACPA-positive and ACPA-negative RA differ, with contrasting associations 
observed at the HLA locus (61,62). Similarly, the environmental factors, smoking and alcohol, 
have been shown to have stronger associations with seropositive RA (2,3). The failure of most 
studies to stratify their analysis by serological status could have affected their findings, with 
the inclusion of a serologically heterogeneous population reducing their power to detect 




As discussed in our introduction, Ren et al have previously systematically reviewed the 
relationship between parity and the risk of RA in women (19). Our systematic review builds 
on their earlier work, by evaluating the association between both parity and gravidity and the 
risk of RA, examining the impact of serology on RA risk, and assessing if risk differs during 
pregnancy, and the post-partum period. We decided to examine the impact of the numbers of 
childbirths and pregnancies on the risk of RA descriptively, primarily because different studies 
used different reference groups when reporting risk, precluding their inclusion in a meta-
analysis. Although Ren et al undertook a dose-response meta-analysis, reporting a significant 
J-shaped relationship between the number of childbirths and RA risk, their meta-analysis 
included (a) two studies examining the effect by the number of pregnancies and not childbirths 
(13,50); (b) two pairs of studies assessing the relationship between RA and parity in the same 
cohorts (with Hernandez Avilla et al (22), and Karlson et al (16) both reporting data from the 
North American Nurses’ Health Study; and Guthrie et al (20), and Ma et al (21) both reporting 
data from the same case-control study conducted in the Seattle area); (c) the mortality rate ratio 
reported by Brun et al for death from RA by number of childbirths (55). Overall, we consider 
that these issues have the potential to affect the accuracy of their findings. 
 
Our analysis has several limitations. Firstly, two cohort studies used documentation of RA on 
the death certificate (55) or hospital admission episode (49) to identify cases; this is likely to 
miss many RA cases. Secondly, the included studies were of variable quality, with the majority 
capturing information on patients’ gravidity and pregnancy status retrospectively using 
questionnaires, increasing the chances of recall bias, which could be a risk for multigravid 
women. Thirdly, all studies were undertaken in North America/Europe, with none performed 
in developing nations, limiting the generalisability of our findings. Fourthly, there was some 




In conclusion, our systematic review does not support the concept that gravidity and parity are 
associated with the risk of RA development. Further research is needed, ideally using 
prospective cohort studies that evaluate risk by serological status and account for key 
confounders such as smoking, to better define environmental risk factors for RA. 
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Table 1. Overview of Included Studies 
 
Study (Year) Design Area  
Gravidity/Parity 
Assessment RA diagnosis Size 
Age 
Range Quality 
Brun et al (1995) (55) Cohort Norway Interview Death certificate  355 RA; 62,735 no RA 32-74 7 (3/2/2) 
Heliövaara et al (1995) (18) Cohort Finland Questionnaire Drug registry  269 RA; 15,172 no RA ≥30 7 (3/2/2) 
Jørgensen et al (2010) (49) Cohort Denmark Registry Hospital admissions 7,017 RA; 2,133,039 no RA 15-69 7 (3/2/2) 
Karlson et al (2004) (16) Cohort USA Questionnaire ACR 1987 674 RA; 103,968 no RA 30-55 7 (2/2/3) 
Lahiri et al (2014) (54) Cohort UK Questionnaire ACR 1987 102 RA; 13,772 no RA 40-79  6 (2/2/2) 
Merlino et al (2003) (50) Cohort USA Questionnaire ACR 1987 158 RA; 31,178 no RA 55-69 6 (3/1/2) 
Brennan et al (1994) (35)a Case-control UK Questionnaire ACR 1987 60 RA; 160 controls 16-45 5 (2/2/1) 
Del Junco et al (1989) (14) Case-control USA Medical records Clinician 324 RA; 324 controls - -c 
Guthrie et al (2010) (20) Case-control USA  Interview ACR 1987 310 RA; 1,418 controls 18-64  6 (3/2/1) 
Hazes et al (1990) (13)b Case-control Netherlands Interview ARA 1958 135 RA; 378 controls 20-50 6 (3/2/1) 
Lansink et al (1993) (12)b Case-control Netherlands Interview ARA 1958 135 RA; 378 controls 20-50 6 (3/2/1) 
Reckner-Olsson et al (2001) (15) Case-control Sweden  Questionnaire ARA 1987 179 RA; 259 controls 25-75 6 (3/2/1) 
Orellana et al (2014) (36) Case-control Sweden  Questionnaire ACR 1987 2,035 RA; 2,911 controls 18-70 6 (3/2/1) 
Pedersen et al (2006) (48) Case-control Denmark Interview ACR 1987 366 RA; 478 controls 18-65 6 (3/2/1) 
Peschken et al (2012) (46) Case-control Canada Questionnaire ACR 1987 168 RA; 400 controls 15->45 7 (4/2/1) 
Pikwer et al (2009) (51) Case-control Sweden Questionnaire ACR 1987 136 RA; 544 controls 44-74 6 (3/2/1) 
Pope et al (1999) (52) Case-control Canada Questionnaire ACR 1987 34 RA; 68 controls 18-44  6 (4/1/1) 
Rodriguez et al (2009) (47) Case-control UK Medical records Clinician 559 RA; 4,234 controls 20-79 6 (3/2/1) 
Silman et al (1992) (11) Case-control UK Interview ACR 1958 88 RA; 144 controls 18-40 6 (4/2/1) 
Spector et al (1990) (53) Case-control UK  Questionnaire ARA 1958 270 RA; 245 controls 35-70 6 (3/2/1) 
 
Study quality was assessed using the Newcastle-Ottawa Score, which provides a total score, and in brackets its individual component breakdown 
(selection/comparability/exposure or outcome); a=Brennan et al included only twins with RA; b=Hazes et al and Lansink et al evaluated different issues in the 
same case-control dataset (one evaluated risk by pregnancy, and the other by timing of pregnancy); c=insufficient data given to assess study quality; 
ACR=American College of Rheumatology; ARA=American Rheumatism Association.  
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Table 2. Risk by Previous Parity and Gravidity Status and by Number of Pregnancies or Childbirths 
Study Risk by Parity and Gravidy Status Risk by Number of Pregnancies or Childbirths 
Brennan et al (35) OR in ever vs. never parous women 2.33 (0.80-6.67)a - 
Brun et al (55) - No significant increased risk (of mortality with RA reported on death certificate) 
by number of childbirths (P-trend 0.66; no depature from linear trend) 
Heliövaara et al (18) RR in ever vs. never parous women 1.06 (0.77-1.46) No significant increased risk by number of childbirths (P-trend RF-positive RA 
0.14; RF-negative RA 0.76; no evidence of departure from linear trend) 
Jørgensen et al (49) RR in ever vs. never parous women 0.96 (0.89-1.04) Using 1 live birth as reference group, significantly reduced risk of RA with 2 and 
3 births, but not ≥4 births (no P-trend reported) 
Karlson et al (16) RR in ever vs. never parous women 0.77 (0.53-1.11)a No significant increased risk for 1, 2, 3 or ≥4 births (nulliparous as reference 
group; no P-trend reported) 
Lahiri et al (54) - Increased risk for ≥2 births vs. no births (HR 2.55; 95% CI 1.19-5.48) but not 1 
birth vs. no births (no P-trend reported) 
Merlino et al (50) OR in ever vs. never parous women 1.14 (0.63-2.05) 
OR in ever vs. never gravid women 1.15 (0.62-2.12) 
Using 1 pregnancy as reference group and excluding nulligravid women no 
increased risk for 2-3, 4-5 or >5 pregnancies (P-trend 0.30) 
Del Junco et al (14) OR in ever vs. never gravid women 0.32 (no CI data) - 
Guthrie et al (20) OR in ever-parous vs. nulligravid women 0.61 (0.43-0.86) 
OR in ever-gravid & nulliparous vs. nulligravid women 1.2 (0.72-
2.00)a 
Using 1 birth as reference group no increased risk for 2, 3, or ≥4 births (P-trend 
not reported but written “not significant”) 
Hazes et al (13) OR in ever-gravid vs. nulligravid women 0.49 (0.27-0.91) Greater risk reduction in women with ≥3 pregnancies than 1-2 pregnancies 
relative to nulligravid (P-trend not reported, both pregnancy categories 
significantly associated with reduced risk) 
Reckner-Olsson et al (15) OR in ever vs. never parous women 0.5 (0.3-0.9) - 
Orellana et al (36) OR in ever vs. never parous women aged 18-44 years 1.1 (0.9-
1.5) and aged 45-70 years 1.0 (0.8-1.2) 
- 
Pedersen et al (48) OR in ever vs. never parous women 0.87 (0.57-1.32) No significant risk reduction for 1,2,3, or ≥4 live births (0 live births as reference 
group; P-trend 0.15) 
Peschken et al (46) - Significant risk reduction in women with ≥6 births and 3 births, but not 4-5 
births, compared with women who had 1-2 births. P-trend=0.046. 
Pikwer et al (51)b OR in ever vs. never parous women 0.75 (0.45-1.24) OR 1.00 (95% CI 0.78-1.27) per number of childbirths (P-trend not reported) 
Pope et al (52) OR in ever vs. never parous women 0.71 (0.26-2.0)a 
OR in ever vs. never gravid women 1.3 (0.5-3.3) 
- 
Spector et al (53) OR in ever vs. never parous women 0.55 (0.31-0.97)a - 
Risk data reported as odds ratios (ORs) or relative risks (RRs) unless otherwise stated; a=risk recalibrated as reported in paper using never vs ever-parous; b=risks 
reported as risk of parity in cases vs. controls, which is equivalent to RA risk in ever-parous vs. nulliparous women; RF=rheumatoid factor. 
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Table 3. Risks in Relation to Pregnancy Timing 
 
Study Risk Reported 
Brennan et al (35) Reported risk during pregnancy (OR 0.95; 95% CI 0.19-4.70) and during 12-month post-partum period (OR 1.02; 95% CI 0.33-
3.16) (reference group not described). 
Del Junco et al (14) Reported risk during pregnancy (RR 0.31) and 12 months post-partum (RR 4.67). No CI data given. 
Guthrie et al (20) Limited data given in manuscript text, with risk reported by duration since last given birth (nulliparous women as reference 
group): last given birth 1-5 years previously RR 0.29 (P<0.001; CI data not given); last given birth 5-15 years previously RR 0.51 
(P<0.001; CI data not given); last given birth >15 years previously RR 0.76 (P=0.18; CI data not given). 
Jørgensen et al (17) Stratified risk by time in years since birth of last child: 0 to <2 years RR 0.99 (95% CI 0.86-1.14); 2-4 years RR 0.95 (95% CI 
0.83-1.08); 5-9 years RR 1.02 (95% CI 0.91-1.13); 10-14 years RR 1.00 (reference); 15-19 years RR 1.06 (95% CI 0.96-1.18); >20 
years RR 1.09 (95% CI 0.98-1.21). 
Lansink et al (12) Risk compared to time period other than pregnancy and the post-partum year: during pregnancy OR 0.64 (95% CI 0.13-3.21); <3 
months post-partum OR 3.37 (95% CI 0.86-13.11); 3-12 months post-partum 0.67 (95% CI 0.13-3.55). 
Orellana et al (36) Assessed risk of RA according to post-partum period for last delivered child (analysis restricted to women aged 18-44 years and 
stratified by ACPA status; time is in years between last delivered child and index year; nulliparous is the reference group):  
 ACPA positive RA - 0 years OR 0.8 (95% CI 0.4-1.6); 1 year OR 0.8 (95% CI 0.4-1.5); 2 years OR 0.6 (95% CI 0.3-1.3). 
 ACPA negative RA - 0 years OR 2.1 (95% CI 0.9-4.8); 1 year OR 1.4 (95% CI 0.6-3.6); 2 years OR 0.8 (95% CI 0.2-2.3). 
Peschken et al (46) OR for RA in 12-months post-partum year was 3.8 (95% CI 1.45-9.93) compared  with >15 years post-partum as the reference 
group. 
Rodriguez et al (47) OR for incident RA in women pregnant in previous 12 months 0.22 (0.06-0.77) 
Silman et al (11) Reported risk during and 12-months after pregnancy (using outside the post-partum period as the reference group): during 
pregnancy OR 0.3 (95% CI 0.04-2.6); 0-3 months post partum OR 5.6 (95% CI 1.80-17.6); 3-12 months post partum OR 2.6 (95% 
CI 0.8-7.9) 
RR=relative risk; OR=OR; CI=confidence interval
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Figure 2. Forest Plot of Risk of Rheumatoid Arthritis in Ever Vs Never Parous Women 
 
The 95% confidence interval data presented in the Forest plot differs slightly from that 
reported in several studies due to using standard errors to derive 95% confidence intervals; 
RE=random effects model; OR=odds ratio; CI=confidence interval; Q=Cochran’s Q-test.    
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Figure 3. Funnel Plot of Studies Included in Meta-Analysis, Augmented Using the 
“Trim and Fill” Method 
 
 
The 11 black circles show the observed effect sizes for the 11 studies; the 2 white circles 
show the augmented “missing” studies of medium precision reporting an increased risk 
associated with being ever-parous. 
  
 
 
